SCHEMBL16434872

SCHEMBL16434872

CC(C)(C)OC(=O)N1CC(OCc2ccc(F)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.49
BACE2 Q9Y5Z0 1/20 0.49
NAAA Q02083 1/20 0.47
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
GPR119 Q8TDV5 2/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
USP30 Q70CQ3 1/20 0.42
NR1H2 P55055 1/20 0.42
KDM1A O60341 1/20 0.41
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41
RORC P51449 2/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21668749 0.90 LIPG (0.49) BACE1BACE2HDAC1HDAC2PRMT5
SCHEMBL23839391 0.90 LIPG (0.49) BACE1BACE2HDAC1HDAC2PRMT5
SCHEMBL18792536 0.88 GPR119 (0.48) BACE1BACE2NAAAPRMT5WDR77
SCHEMBL13590834 0.87 GPR119 (0.52) PRMT5WDR77GPR119DDB1CRBN
SCHEMBL31043692 0.87 PRMT5 (0.44) BACE1BACE2PRMT5WDR77GPR119
SCHEMBL17274387 0.87 USP30 (0.47) BACE1BACE2PRMT5WDR77GPR119
SCHEMBL25295010 0.87 PRMT5 (0.44) BACE1BACE2PRMT5WDR77GPR119
SCHEMBL9938446 0.86 PRMT5 (0.51) BACE1BACE2PRMT5WDR77GPR119
SCHEMBL3123833 0.85 LIPE (0.52) PRMT5WDR77GPR119DDB1CRBN
SCHEMBL1769009 0.84 GPR119 (0.54) BACE1BACE2PRMT5WDR77GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206748-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2025-06-26 US disclosed
EP-4335497-A2 PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. Lundbeck A/S (DK) 2024-03-13 EP disclosed
EP-3865484-B1 PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H LUNDBECK AS (DK) 2023-11-08 EP disclosed
EP-3865484-B1 PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H LUNDBECK AS (DK) 2023-11-08 EP disclosed
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2023-06-15 US disclosed
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2023-06-15 US disclosed
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2023-06-15 US disclosed
US-11608342-B2 PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases H. LUNDBECK A/S (DK) 2023-03-21 US disclosed
CN-114903900-A PDE9 inhibitors for the treatment of peripheral diseases 伊马拉公司 2022-08-16 CN disclosed
EP-3865484-A1 PDE9 INHIBITOR WITH IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. Lundbeck A/S (DK) 2021-08-18 EP disclosed
US-10513524-B2 PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases H. LUNDBECK A/S (DK) 2019-12-24 US disclosed
US-10513524-B2 PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases H. LUNDBECK A/S (DK) 2019-12-24 US disclosed
US-20190307754-A1 PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES IMARA, INC. 2019-10-10 US disclosed
US-20190307754-A1 PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES IMARA, INC. 2019-10-10 US disclosed
US-20180194770-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2018-07-12 US disclosed
US-20180194770-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2018-07-12 US disclosed
US-20180194770-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES H. LUNDBECK A/S (DK) 2018-07-12 US disclosed
US-9403798-B2 Triazinone compound and T-type calcium channel inhibitor NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-08-02 US disclosed
US-20150065705-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2015-03-05 US disclosed
EP-2832728-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR Nissan Chemical Industries, Ltd. (JP) 2015-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11608342-B2 PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases PDE9A, PDE5A, PDE3A BACE1 4064/4885BACE2 4164/4885NAAA 3381/4885
US-20250206748-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES PDE9A, PDE5A, PDE3A BACE1 4064/4885BACE2 4164/4885NAAA 3381/4885
US-10513524-B2 PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases PDE9A, PDE5A, PDE3A BACE1 4064/4885BACE2 4164/4885NAAA 3381/4885
US-20190307754-A1 PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES PDE9A, PDE12, PDE5A BACE1 2027/4885BACE2 1781/4885NAAA 2636/4885
US-20180194770-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES PDE9A, PDE5A, PDE3A BACE1 4064/4885BACE2 4164/4885NAAA 3381/4885
US-20230183255-A1 PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES PDE9A, PDE5A, PDE3A BACE1 4064/4885BACE2 4164/4885NAAA 3381/4885
US-20150065705-A1 TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1E, CACNA1I, CACNA1G BACE1 520/4885BACE2 478/4885NAAA 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.